Clinical Trials

51 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03981705 2024-12-27

Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer

Completed

8 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02266420 2024-12-03

COCABIO000

Phase NA Completed

151 enrolled

Triple Negative Breast Neoplasms

NCT03487666 2024-12-03

OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease

45 enrolled 15 charts

Triple Negative Breast Neoplasms

NCT04111510 2024-11-21

Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer

6 enrolled 13 charts

Triple Negative Breast Neoplasms

NCT03356860 2024-11-20

B-IMMUNE

Phase 1/2 Completed

57 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02938442 2024-11-07

Vaccination of Triple Negative Breast Cancer Patients

Phase 1/2 Completed

16 enrolled 30 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03004183 2024-10-15

STOMP

57 enrolled 12 charts

BreastThoracic

Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

NCT03164993 2024-10-15

ALICE

68 enrolled

Breast Neoplasms, Neoplasms, Triple Negative Breast Neoplasms

NCT03207529 2024-10-10

Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer

18 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02689427 2024-09-19

Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer

24 enrolled 7 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05111067 2024-08-21

Molecular Subtyping of Triple-negative Breast Cancer and African Ancestry-related Immunogenicity

Completed

120 enrolled

Triple Negative Breast Neoplasms

NCT04464174 2024-07-26

PATHFINDER

54 enrolled

Triple Negative Breast Neoplasms

NCT04408118 2024-06-04

ATRACTIB

100 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02996825 2024-04-02

Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer

44 enrolled

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04134884 2024-03-22

Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

34 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02648477 2024-03-19

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

30 enrolled 11 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06309459 2024-03-13

Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma

Completed

40 enrolled

Triple Negative Breast Neoplasms

NCT03853707 2024-02-20

Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer

Phase 1/2 Completed

28 enrolled 12 charts

Triple Negative Breast Neoplasms

NCT02456857 2024-02-13

Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

17 enrolled 8 charts

Triple Negative Breast Neoplasms

NCT03012230 2024-01-31

Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer

12 enrolled